Background: Lupus nephritis (LN) is a major determinant of mortality in systemic lupus erythematosus (SLE). Here we evaluated the association between complete renal response (CR) and mortality in LN. Methods: We retrospectively analyzed the cases of 172 of 201 patients with LN for whom data on the therapeutic response at 6 and 12 months after induction therapy were available. The patients underwent a renal biopsy at Nagasaki University Hospital and community hospitals in Nagasaki between the years 1990 and 2016. We determined the CR rates at 6 and 12 months after induction therapy initiation and evaluated the predictive factors for CR and their relationship with mortality. We performed univariate and multivariable competing risks regression analyses to determine the factors predictive of CR. The patients' survival data were analyzed by the Kaplan-Meier method with a log-rank test. Results: The median follow-up duration after renal biopsy was 120 months (interquartile range: 60.3-191.8 months). The 5-, 10-, 15-and 20-year survival rates of our cohort were 99.3, 94.6, 92.0 and 85.4%, respectively. During follow-up, nine patients (5.2%) died from cardiovascular events, infection, malignancy and other causes. The multivariate analysis revealed that the following factors were predictive of CR. At 6 months: male gender (odds ratio (OR) 0.23, 95% confidence interval (CI) 0.08-0.65, p ¼ 0.0028), proteinuria (g/gCr) (OR 0.83, 95% CI 0.71-0.97, p ¼ 0.0098) and index of activity (0-24) (OR 0.84, 95% CI 0.71-0.99, p ¼ 0.0382). At 12 months: male gender (OR 0.25, 95% CI 0.09-0.67, p ¼ 0.0043) and index of activity (0-24) (OR 0.82, p ¼ 0.0236). The Kaplan-Meier analysis showed that compared to not achieving CR at 12 months, achieving CR at 12 months was significantly correlated with the survival rate (OR 0.18, 95% CI 0.04-0.92, p ¼ 0.0339). Conclusions: Our results suggest that the survival rate of patients with LN is associated with the achievement of CR at 12 months after induction therapy, and that male gender and a higher index of activity (0-24) are the common predictive factors for failure to achieve CR at 6 and 12 months. Lupus (2019) 28, 295-303.
Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with a broad spectrum of clinical and immunologic manifestations, among which lupus nephritis (LN) is the most common cause of morbidity and mortality. 1 Indeed, SLE patients with LN have 6-6.8-fold higher standardized mortality rates compared to those without LN (2.4-fold). [2] [3] [4] [5] Notably, over the past few decades, the 10-year survival rate of LN has improved dramatically from 46 to 95% among patients in whom disease remission can be achieved. 6 Nonetheless, approximately 5-20% of patients with LN will progress to end-stage renal disease (ESRD) within 10 years after diagnosis despite receiving aggressive immunosuppressive therapy. [7] [8] [9] Although the causes and prognostic predictors of renal outcomes and mortality in LN have been studied, there is only limited data on LN in Japan. The recommendations for LN management published by the European League Against Rheumatism (EULAR)/European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) propose that a complete renal response (CR) or at least a partial renal response (PR) should be achieved preferably within 6 months and no later than 12 months after the initiation of treatment. 10 Various demographic, clinical and experimental variables have been associated with poor outcomes in LN, including age, gender, ethnicity, duration of disease, uncontrolled hypertension, anemia, elevation of serum creatinine, reduction of the glomerular filtration rate and chronic kidney disease. 5, 11 However, only a few clinical immunological parameters have been determined to be predictive of achieving CR at 6 and 12 months.
We conducted the present study to evaluate the causes of mortality in biopsy-proven LN patients and to identify the factors predictive of renal outcome and mortality among the LN patients treated at Nagasaki University Hospital and community hospitals in Nagasaki, Japan.
Patients and methods
We conducted an analysis of the retrospectively collected data of 201 patients with biopsy-proven LN treated between 1990 and 2016 at Nagasaki University Hospital and community hospitals in Nagasaki. To obtain the pathological information of the patients with LN, biopsy specimens were reclassified separately by two expert nephropathologists (MK and TT) based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification, 12, 13 regardless of the patients' previous World Health Organization or ISN/RPS classification. Patients were excluded if they had advanced comorbidity or other diseases associated with kidney dysfunction, including diabetic kidney disease or primary kidney disease. Patients with inadequate medical records or follow-up periods < 12 months were also excluded from this study. All patients were followed at 1-3-month intervals, from the time of renal biopsy for !12 months.
We divided the 201 patients based on whether or not they achieved CR, and we compared the two groups to identify predictors of achieving CR at 6 and 12 months of treatment. The CR group was defined as achieving CR at 6 and 12 months with prednisolone and/or immunosuppressive treatment, and those without CR formed the non-CR group. Some of the patients provided written informed consent for the use of their data, and an opt-out strategy was chosen for the remaining patients. Those who rejected informed consent were excluded. The study was reviewed and approved by the Medical Ethical Committee of Nagasaki University Hospital (approval numbers 12012397 and 17082129).
Data collection
Baseline characteristics were collected at the time of renal biopsy. Demographic data included the patient's age at the onset of SLE, gender, the disease duration of SLE (the time from the diagnosis of SLE until the renal biopsy), comorbidities of Sjo¨gren syndrome/antiphospholipid syndrome and the induction treatment used. We analyzed the patients' laboratory data, including white blood cell count, lymphocyte count, hemoglobin, platelet count, albumin, proteinuria, urine protein/ creatinine ratio (Up/Ucr), urinary N-acetyl-b-Dglucosaminidase, urinary b2-microglobulin, serum b2-microglobulin, serum creatinine (Cr), blood urea nitrogen (BUN) and estimated glomerular filtration rate (eGFR), as well as immunologic parameters including complement 3 (C3), complement 4 (C4), total hemolytic complement (CH50), immunoglobulin (Ig)G, IgA, IgM, antinuclear antibodies, anti-double-stranded DNA (dsDNA) antibodies, anti-Smith (Sm) antibodies, antiribonucleoprotein (RNP) antibodies, anti-Ro/SSA antibodies and anti-La/SSB antibodies. Histologic features of activity and chronicity scores were determined as described previously. 14 
Treatment and the definition of renal remission
The patients were treated with immunosuppressive agents, depending on the clinical judgment of a rheumatologist and the treatment guidelines/recommendations for LN published by the American College of Rheumatology and EULAR/ERA-EDTA. 10, 15 Therapies included prednisolone (PSL) with intravenous cyclophosphamide (IVCY; 500-1000 mg/m 2 body surface area once a month for six months), or PSL with the first-line immunosuppressive regimen used for the treatment of LN, followed by quarterly IVCY or oral immunosuppressants. PSL was given at the dose of 0.5-1 mg/ kg/day, with or without intravenous methylprednisolone (mPSL) pulse therapy (500-1000 mg/day Â 3 days). Plasma exchange was performed for patients who were resistant to other treatments.
At the discretion of the treating physician, induction therapy was implemented for a period of approximately 6 months. We defined CR at 6 and 12 months as an Up/Ucr ratio < 50 mg/mmol (roughly equivalent to proteinuria <0.5 g/24 hr) and a normal or near-normal (within 10% of a normal glomerular filtration rate (GFR) if previously abnormal) GFR. We defined PR as a !50% reduction in proteinuria to subnephrotic levels and a normal or near-normal GFR.
Mortality, causes of death and occurrence of ESRD
The primary outcome was mortality due to any cause. The secondary outcome was ESRD, defined as dialysis dependence for >3 months. Data were collected until either the patient's final follow-up or until 30 July 2018, whichever occurred later. Risk factors for mortality were determined.
Statistical analyses
A non-parametric Wilcoxon rank sum test was used for inter-group comparisons of multiple variables. Fisher's exact test or chi-squared test was also used to test the possible association between each variable factor and the treatment response. We performed univariate and multivariable competing risks regression analyses to determine the predictive factors of clinical response. The data on the time to death or the duration of survival after renal biopsy were analyzed using the Kaplan-Meier method with a log-rank test. All of the statistical analyses were performed using JMP Pro14 software (SAS Institute, Cary, NC, USA). The significance level was set at p < 0.05.
Results

Baseline characteristics of the studied patients
Among the total 201 cases, we were able to examine the therapeutic responses of 172 patients at 6 and 12 months after initiation of therapy ( Figure 1 ). The demographic and disease-related features of the 172 patients are shown in Supplemental We divided the 172 patients into two groups based on their CR status at 6 months (Table 1) and 12 months (Table 2 ) after induction therapy. Seventy-nine patients (45.9%) achieved CR at 6 months, and 101 patients (58.7%) achieved CR at 12 months. Among the disease-related features at baseline, a higher percentage of males (p ¼ 0.0106), the amount of proteinuria (p < 0.0001), the percentage of ISN/RPS Class III or IV (p ¼ 0.0036), a higher index of activity (0-24) (p ¼ 0.0002) and chronicity (0-12) (p ¼ 0.0034) were significantly related to failure to achieve CR at 6 months. Factors predictive of long-term mortality in LN K Ichinose et al.
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Lupus Table 2 Baseline characteristics of patients who did or did not achieve complete renal response at 12 months Twenty-year survival rates of the cohort
The 5-, 10-, 15-and 20-year survival rates of our cohort were 99.3, 94.6, 92.0 and 85.4%, respectively. There were a total of nine deaths (5.2%) with the main causes being cardiovascular disease (n ¼ 3, 33.3%), infection (n ¼ 1, 11.1%) and malignancy (n ¼ 1, 11.1%). Four (44.4%) patients died from other causes; one patient died from a pulmonary hemorrhage, one died of lupus enterocolitis, and the cause of death in the other two patients was not known (Supplemental Table 2 ). Eight of the nine patients had a disease duration in excess of 5 years.
The patients who died during the observation period were significantly older at the onset of LN (42 versus 34 years, p ¼ 0.0256), had significantly higher serum Cr at the onset of LN (0.9 versus 0.7 mg/dl, p ¼ 0.0237) and had a significantly lower eGFR at the onset of LN (56.4 versus 78.7 ml/min/1.73 m 2 , p ¼ 0.0190) compared to the non-fatalities.
Predictors of CR at 6 months and 12 months after induction therapy
The multivariate logistic analysis revealed that male gender (odds ratio (OR) 0.23, 95% confidence interval (CI) 0.08-0.65, p ¼ 0.0028), proteinuria (g/gCr) (OR 0.83, 95% CI 0.71-0.97, p ¼ 0.0098) and index of activity (0-24) (OR 0.84, 95% CI 0.71-0.99, p ¼ 0.0382) were predictive of achieving CR at 6 months after induction therapy (Table 3) , and male gender (OR 0.25, 95% CI 0.09-0.67, p ¼ 0.0043) and the index of activity (0-24) (OR 0.82, 95% CI 0.69-0.98, p ¼ 0.0236) were predictive of achieving CR at 12 months (Table 4) .
Analysis of survival rate: CR at 6 months and 12 months
Six patients (3.5%) progressed to ESRD and nine patients (5.2%) died during the observation period. The Kaplan-Meier analysis showed that compared to not achieving CR at 12 months, the achievement of CR at 12 months (Figure 2(b) ) was significantly correlated with the survival rate, whereas no such correlation was shown for the achievement of CR at 6 months (Figure 2(a) ). The renal survival rate was not correlated with the achievement of CR at 6 or 12 months (Supplemental Figure 1) .
Discussion
LN can result in serious organ damage, and among patients with SLE, the presence or absence of LN is related to mortality. 7, 16 Several studies have conducted short-to medium-term follow-ups of survival and renal outcomes in LN. However, few studies have examined the long-term prognosis in LN (i.e. over a follow-up period >10 years). 5, [17] [18] [19] [20] [21] [22] [23] [24] To our knowledge, the present study is the first to show an association between the long-term survival rate and therapeutic responses in a cohort of Japanese patients with LN. We found that the 5-, 10-, 15-and 20-year survival rates in our cohort were 99.3, 94.6, 92.0 and 85.4%, respectively, which were comparable to the previously reported survival rates. 2, 5, 19 The survival rate of our LN patients was significantly correlated with the achievement of CR at 12 months after induction therapy. A previous study found that the survival rate was greater in patients who achieved CR or PR than in those with no remission. 6 Another report showed that patients who achieved CR at 24 months after biopsy were significantly less likely to experience ESRD/mortality compared to patients who were not in remission. 25 However, these studies did not discuss the reasons for the survival rate and therapeutic responses in LN.
A few baseline variables have emerged as risk factors for fatalities. The mortality was markedly increased for older patients in previous studies, and age was one of the baseline predictors of death in a cohort of patients with LN. 5, 26 Elevated serum Cr is also reported to be associated with an increased risk of mortality. 26, 27 Impairment of renal function with a reduced eGFR at the baseline was reported to be associated with mortality. 28, 29 We speculated that if patients with LN who achieved CR are less exposed to immunosuppressive agents (such as cyclophosphamide and high-dose corticosteroid) and also have a less severe inflammatory condition, they might be less vulnerable to organ damage than patients with LN who fail to achieve CR.
In our cohort, cardiovascular complications, malignancy and infection were the leading causes of mortality, and this is similar to other reports. 2, 7 Due to advances in immunosuppressive treatment, supportive therapy, socio-economic conditions and earlier diagnoses, the survival of individuals with LN has improved significantly over the past few decades. LN-related causes of death including uncontrolled disease or acute renal failure are now rare. However, infection remains an important cause of mortality, and cardiovascular and malignancy complications with longer patient survival have emerged as important causes of late mortality. 2, 3 In our study, 79 patients (45.9%) achieved CR at 6 months and 101 patients (58.7%) achieved CR at 12 months. These results are similar to those of previous studies, which reported remission rates of 33.0-50.4% at 6 months and 49.3-58.0% at 12 months. [30] [31] [32] The significance of achieving CR on the long-term prognosis of LN has been described in many studies. We demonstrated that male gender and a higher index of activity (0-24) were the common predictive factors for the failure to achieve CR at 6 and 12 months. It has also been shown that male patients responded less to treatment and had a poorer course. 24, 26, 33 In the Hopkins lupus cohort, there was a doubled odds of renal biopsy, renal insufficiency and renal failure among males compared to females, with adjustment for age, duration of SLE, ethnicity and smoking status. 34 In that cohort, male gender was also associated with a 2-fold greater risk of death. 35 Wang et al. 33 showed that males with LN had significantly lower remission rates at 6 months after starting treatment, which is similar to our present finding. In our study, there were more male LN patients whose onset was at age !50 years (p ¼ 0.0310, data not shown). As mentioned above, later onset of LN with older age is linked to poorer renal outcome and mortality. However, according to a recent critical review of the literature, 36 the concept of worse prognoses in males compared to females with LN remains controversial in light of the limited evidence.
A higher index of activity (0-24) is known to be a predictor of poorer renal outcome and mortality. 26, [37] [38] [39] However, other studies failed to demonstrate a relationship between the index of activity Figure 2 Kaplan-Meier analysis of the cumulative survival rate, according to the achievement of complete renal response (CR) at 6 (a) and 12 (b) months. The red line indicates the number of patients who had achieved CR, and the blue line indicates the number who had not achieved CR at each time point. The raw numbers of patients analyzed in each subset at each time point are included below the figures; these were patients whose survival was considered to be ''at risk. '' and the course of LN. 40 As a potential alternative marker, other investigations have shown that a combined activity and chronicity index has a strong predictive value in the course of LN. 41 The limitations of our study deserve some discussion. First, our cohort included a relatively small number of patients with few fatalities treated at a university hospital and community hospitals in a rural area. Second, it is difficult to generalize in regard to previously adopted risk factors for mortality and therapeutic response because different response criteria and various observation periods were used in the past and present investigations. Third, because we used a long-term follow-up period, the therapeutic regimens of the patients could have differed between our study and the previous ones; in particular, we could not enroll patients who were treated with hydroxychloroquine (HCQ). Because HCQ for SLE patients was approved relatively recently in Japan (in September 2015), the percentage of patients excluded due to HCQ use would have been greater in our study than in the previous investigations. Further observational studies of larger multicenter populations are required to test our findings and to further assess the clinical relevance of mortality and the attainment of CR at 12 months.
In conclusion, we retrospectively analyzed the association between the mortality rate and therapeutic responses with a mean 10-year follow-up in LN. We found that the survival rate was associated with the achievement of CR at 12 months after induction therapy. In addition, male gender and a higher index of activity (0-24) were the common predictive factors for failure to achieve CR at 6 and 12 months. Our results suggest that the attainment of CR at 12 months could predict the survival rate and that male patients and the histological score should be carefully followed for the prediction of renal outcomes and the prevention of renal flares.
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